During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub spoke to Gabriela Hobbs, Massachusetts General Hospital, Boston, US. We asked: How can we predict and reduce the risk of thrombosis in a patient with polycythemia vera (PV)?
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
How can we predict and reduce the risk of thrombosis in a patient with PV?
How can we predict and reduce the risk of thrombosis in a patient with PV?
Patients with PV are at an increased risk of experiencing thrombotic complications, and cardiovascular events are the leading cause of death in these patients. Here, Gabriela Hobbs outlines the key risk factors and some of the driving biological processes for thrombosis in patients with PV.
A number of factors determine a patient's risk of thrombosis, including age and lifestyle factors. Here, Gabriela Hobbs describes how to manage patients on an individual basis to reduce the risk of thrombosis.
Your opinion matters
What will be the hot topics at ASH 2020 for MPN?
1 vote - 6 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox